Analysis of serum macrophage migration inhibitory factor and D-dopachrome tautomerase in systemic sclerosis

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Objectives: Macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (DDT), members of the same cytokine superfamily, are linked to the pathogenesis of a number of inflammatory diseases. The aim of this study was to investigate their clinical relevance in systemic sclerosis (SSc). Methods: Serum MIF and DDT were quantified in 105 SSc patients by ELISA and levels compared to healthy controls (HC) (47) and patients with systemic lupus erythematosus (SLE) (184). Clinical parameters included organ involvement, serum laboratory markers and results of pulmonary function tests, and overall disease activity assessed using the European Scleroderma Trials and Research group (EUSTAR) activity index. Results: There was no significant difference in serum DDT concentrations between patients with SSc and HC. However, serum MIF was significantly increased in SSc compared to both HC and SLE cohorts. Serum MIF was increased in SSc patients with low forced vital capacity (FVC) and was also associated with the use of angiotensin II receptor blockers and beta blockers in SSc, confirmed after adjusting for the presence of systemic hypertension and low FVC. Serum DDT was significantly higher in SSc patients with low FEV1 and negatively correlated with EUSTAR score, particularly in patients with limited disease. Conclusion: Although not significantly linked to specific clinical parameters, serum MIF was significantly higher in SSc patients than in HC and SLE patients, suggesting a fundamental role for MIF in SSc. DDT, while closely related to MIF, did not show a similar expression profile, suggesting functional differences between these molecules.

Original languageEnglish
Article numbere1042
Number of pages10
JournalClinical and Translational Immunology
Volume7
Issue number12
DOIs
Publication statusPublished - 1 Jan 2018

Keywords

  • biomarker
  • cytokine
  • systemic lupus erythematosus (SLE)
  • systemic sclerosis

Cite this

@article{cd3ff8c7480b40cdb9ba3b10fa61792e,
title = "Analysis of serum macrophage migration inhibitory factor and D-dopachrome tautomerase in systemic sclerosis",
abstract = "Objectives: Macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (DDT), members of the same cytokine superfamily, are linked to the pathogenesis of a number of inflammatory diseases. The aim of this study was to investigate their clinical relevance in systemic sclerosis (SSc). Methods: Serum MIF and DDT were quantified in 105 SSc patients by ELISA and levels compared to healthy controls (HC) (47) and patients with systemic lupus erythematosus (SLE) (184). Clinical parameters included organ involvement, serum laboratory markers and results of pulmonary function tests, and overall disease activity assessed using the European Scleroderma Trials and Research group (EUSTAR) activity index. Results: There was no significant difference in serum DDT concentrations between patients with SSc and HC. However, serum MIF was significantly increased in SSc compared to both HC and SLE cohorts. Serum MIF was increased in SSc patients with low forced vital capacity (FVC) and was also associated with the use of angiotensin II receptor blockers and beta blockers in SSc, confirmed after adjusting for the presence of systemic hypertension and low FVC. Serum DDT was significantly higher in SSc patients with low FEV1 and negatively correlated with EUSTAR score, particularly in patients with limited disease. Conclusion: Although not significantly linked to specific clinical parameters, serum MIF was significantly higher in SSc patients than in HC and SLE patients, suggesting a fundamental role for MIF in SSc. DDT, while closely related to MIF, did not show a similar expression profile, suggesting functional differences between these molecules.",
keywords = "biomarker, cytokine, systemic lupus erythematosus (SLE), systemic sclerosis",
author = "Vincent, {Fabien Bernard} and Emily Lin and Joanne Sahhar and Ngian, {Gene Siew} and Kandane-Rathnayake, {Rangi Kaushalya} and Rachel Mende and Alberta Hoi and Morand, {Eric F.} and Tali Lang and James Harris",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/cti2.1042",
language = "English",
volume = "7",
journal = "Clinical and Translational Immunology",
issn = "2050-0068",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Analysis of serum macrophage migration inhibitory factor and D-dopachrome tautomerase in systemic sclerosis

AU - Vincent, Fabien Bernard

AU - Lin, Emily

AU - Sahhar, Joanne

AU - Ngian, Gene Siew

AU - Kandane-Rathnayake, Rangi Kaushalya

AU - Mende, Rachel

AU - Hoi, Alberta

AU - Morand, Eric F.

AU - Lang, Tali

AU - Harris, James

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objectives: Macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (DDT), members of the same cytokine superfamily, are linked to the pathogenesis of a number of inflammatory diseases. The aim of this study was to investigate their clinical relevance in systemic sclerosis (SSc). Methods: Serum MIF and DDT were quantified in 105 SSc patients by ELISA and levels compared to healthy controls (HC) (47) and patients with systemic lupus erythematosus (SLE) (184). Clinical parameters included organ involvement, serum laboratory markers and results of pulmonary function tests, and overall disease activity assessed using the European Scleroderma Trials and Research group (EUSTAR) activity index. Results: There was no significant difference in serum DDT concentrations between patients with SSc and HC. However, serum MIF was significantly increased in SSc compared to both HC and SLE cohorts. Serum MIF was increased in SSc patients with low forced vital capacity (FVC) and was also associated with the use of angiotensin II receptor blockers and beta blockers in SSc, confirmed after adjusting for the presence of systemic hypertension and low FVC. Serum DDT was significantly higher in SSc patients with low FEV1 and negatively correlated with EUSTAR score, particularly in patients with limited disease. Conclusion: Although not significantly linked to specific clinical parameters, serum MIF was significantly higher in SSc patients than in HC and SLE patients, suggesting a fundamental role for MIF in SSc. DDT, while closely related to MIF, did not show a similar expression profile, suggesting functional differences between these molecules.

AB - Objectives: Macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (DDT), members of the same cytokine superfamily, are linked to the pathogenesis of a number of inflammatory diseases. The aim of this study was to investigate their clinical relevance in systemic sclerosis (SSc). Methods: Serum MIF and DDT were quantified in 105 SSc patients by ELISA and levels compared to healthy controls (HC) (47) and patients with systemic lupus erythematosus (SLE) (184). Clinical parameters included organ involvement, serum laboratory markers and results of pulmonary function tests, and overall disease activity assessed using the European Scleroderma Trials and Research group (EUSTAR) activity index. Results: There was no significant difference in serum DDT concentrations between patients with SSc and HC. However, serum MIF was significantly increased in SSc compared to both HC and SLE cohorts. Serum MIF was increased in SSc patients with low forced vital capacity (FVC) and was also associated with the use of angiotensin II receptor blockers and beta blockers in SSc, confirmed after adjusting for the presence of systemic hypertension and low FVC. Serum DDT was significantly higher in SSc patients with low FEV1 and negatively correlated with EUSTAR score, particularly in patients with limited disease. Conclusion: Although not significantly linked to specific clinical parameters, serum MIF was significantly higher in SSc patients than in HC and SLE patients, suggesting a fundamental role for MIF in SSc. DDT, while closely related to MIF, did not show a similar expression profile, suggesting functional differences between these molecules.

KW - biomarker

KW - cytokine

KW - systemic lupus erythematosus (SLE)

KW - systemic sclerosis

UR - http://www.scopus.com/inward/record.url?scp=85058689987&partnerID=8YFLogxK

U2 - 10.1002/cti2.1042

DO - 10.1002/cti2.1042

M3 - Article

VL - 7

JO - Clinical and Translational Immunology

JF - Clinical and Translational Immunology

SN - 2050-0068

IS - 12

M1 - e1042

ER -